Literature DB >> 22067311

Early changes in kidney function predict long-term chronic kidney disease and mortality in patients after liver transplantation.

Marcelo Cantarovich1, Jean Tchervenkov, Steven Paraskevas, Peter Ghali, Philip Wong, Marc Deschênes, Prosanto Chaudhury, Mazen Hassanain, Dionisios Vrochides, Peter Metrakos, Jeffrey Barkun.   

Abstract

BACKGROUND: Chronic kidney disease (CKD) is a well-known complication after liver transplantation (LT) and is associated with increased mortality. The purpose of this study was to determine risk factors of advanced CKD and mortality after LT.
METHODS: Four hundred forty-five adult patients underwent LT between June 1990 and September 2007 and survived more than 1 month. Multivariate Cox regression analyses were performed for time to CKD stage 4 (glomerular filtration rate [GFR] ≤30 mL/min), time to chronic dialysis, and all-cause mortality. Several patient and disease characteristics were used as independent pre- and posttransplant variables. We specifically analyzed a drop more than or equal to 30% in the estimated GFR (eGFR) during the first year posttransplant.
RESULTS: Diabetes mellitus pretransplant and a drop more than or equal to 30% in the eGFR between 3 and 12 months predicted CKD stage 4 (odds ratio [OR] 4.1, 95% confidence interval [CI] 1.9-5.4, P<0.001 and OR 16.1, 95% CI 5.9-44.5, P<0.0001, respectively), the need for chronic dialysis (OR 3.8, 95% CI 1.1-13.2, P=0.03 and OR 14.6, 95% CI 3.0-71.4, P<0.001, respectively), and all-cause mortality (OR 1.9, 95% CI 1.2-2.9, P=0.004 and OR 2.6, 95% CI 1.6-4.4, P<0.001, respectively), more than 1 year after LT.
CONCLUSIONS: Diabetes mellitus pretransplant and a drop more than or equal to 30% in the eGFR within the first year are strong predictors of advanced CKD, chronic dialysis, and death more than 1 year after LT. These easily determined clinical variables define a population at risk for CKD who should be targeted for renal protection strategies.

Entities:  

Mesh:

Year:  2011        PMID: 22067311     DOI: 10.1097/TP.0b013e3182384aff

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  11 in total

1.  Early Postoperative Neutrophil Gelatinase-Associated Lipocalin Predicts the Development of Chronic Kidney Disease After Liver Transplantation.

Authors:  Giuseppe Cullaro; Joseph F Pisa; Robert S Brown; Gebhard Wagener; Elizabeth C Verna
Journal:  Transplantation       Date:  2018-05       Impact factor: 4.939

Review 2.  Keys to long-term care of the liver transplant recipient.

Authors:  Kymberly D Watt
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-10-13       Impact factor: 46.802

3.  Underestimation of chronic renal dysfunction after liver transplantation: ICEBERG study.

Authors:  Evaristo Varo; Rafael Bañares; Magda Guilera
Journal:  World J Transplant       Date:  2015-03-24

4.  Risk of end-stage renal disease among liver transplant recipients with pretransplant renal dysfunction.

Authors:  R Ruebner; D Goldberg; P L Abt; R Bahirwani; M Levine; D Sawinski; R D Bloom; P P Reese
Journal:  Am J Transplant       Date:  2012-07-03       Impact factor: 8.086

5.  Comparing 10-yr renal outcomes in deceased donor and living donor liver transplants.

Authors:  Shaifali Sandal; Anthony Almudevar; Sandesh Parajuli; Anirban Bose
Journal:  Clin Transplant       Date:  2015-11-05       Impact factor: 2.863

6.  Risk factors for new-onset chronic kidney disease in patients who have received a liver transplant.

Authors:  Yuehong Li; Binbin Li; Wei Wang; Jiaxuan Lv
Journal:  Exp Ther Med       Date:  2018-01-31       Impact factor: 2.447

7.  Prolonged lymphopenia following anti-thymocyte globulin induction is associated with decreased long-term graft survival in liver transplant recipients.

Authors:  D Vrochides; M Hassanain; P Metrakos; J Tchervenkov; J Barkun; P Chaudhury; M Cantarovich; S Paraskevas
Journal:  Hippokratia       Date:  2012-01       Impact factor: 0.471

8.  Everolimus and early calcineurin inhibitor withdrawal: 3-year results from a randomized trial in liver transplantation.

Authors:  M Sterneck; G M Kaiser; N Heyne; N Richter; F Rauchfuss; A Pascher; P Schemmer; L Fischer; C G Klein; S Nadalin; F Lehner; U Settmacher; P Neuhaus; D Gotthardt; M Loss; S Ladenburger; E M Paulus; M Mertens; H J Schlitt
Journal:  Am J Transplant       Date:  2014-02-06       Impact factor: 8.086

9.  Renal Protective Effect of Everolimus in Liver Transplantation: A Prospective Randomized Open-Label Trial.

Authors:  Zakiyah Kadry; Jonathan G Stine; Takehiko Dohi; Ashokkumar Jain; Kimberly L Robyak; Osun Kwon; Christopher J Hamilton; Piotr Janicki; Thomas R Riley; Fauzia Butt; Karen Krok; Ian R Schreibman; Dmitri Bezinover; Nasrollah Ghahramani; Stalin Campos; Christopher S Hollenbeak
Journal:  Transplant Direct       Date:  2021-06-08

10.  Fluctuations of Estimated Glomerular Filtration Rate Outside Kidney Disease Improving Global Outcomes Diagnostic Criteria for Acute Kidney Injury in End-Stage Liver Disease Outpatients and Outcome Postliver Transplantation.

Authors:  Federica Fiacco; Fabio Melandro; Ilaria Umbro; Assunta Zavatto; Andrea Cappoli; Edoardo Poli; Stefano Ginanni Corradini; Manuela Merli; Francesca Tinti; Italo Nofroni; Pasquale B Berloco; Massimo Rossi; Anna Paola Mitterhofer
Journal:  Transplant Direct       Date:  2017-10-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.